Cargando…

Statin use and all-cause and cancer mortality: BioBank Japan cohort

BACKGROUND: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokomichi, Hiroshi, Nagai, Akiko, Hirata, Makoto, Tamakoshi, Akiko, Kiyohara, Yutaka, Kamatani, Yoichiro, Muto, Kaori, Ninomiya, Toshiharu, Matsuda, Koichi, Kubo, Michiaki, Nakamura, Yusuke, Yamagata, Zentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350595/
https://www.ncbi.nlm.nih.gov/pubmed/28196737
http://dx.doi.org/10.1016/j.je.2016.12.011
_version_ 1782514693508694016
author Yokomichi, Hiroshi
Nagai, Akiko
Hirata, Makoto
Tamakoshi, Akiko
Kiyohara, Yutaka
Kamatani, Yoichiro
Muto, Kaori
Ninomiya, Toshiharu
Matsuda, Koichi
Kubo, Michiaki
Nakamura, Yusuke
Yamagata, Zentaro
author_facet Yokomichi, Hiroshi
Nagai, Akiko
Hirata, Makoto
Tamakoshi, Akiko
Kiyohara, Yutaka
Kamatani, Yoichiro
Muto, Kaori
Ninomiya, Toshiharu
Matsuda, Koichi
Kubo, Michiaki
Nakamura, Yusuke
Yamagata, Zentaro
author_sort Yokomichi, Hiroshi
collection PubMed
description BACKGROUND: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. METHODS: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. Kaplan–Meier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. RESULTS: Our cohort included 41,930 patients with mean ages of 64–66 years and mean body mass indices of 24–25 kg/m(2). Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. CONCLUSIONS: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statin monotherapy could potentially reduce any-organ- and colorectal cancer-related mortality.
format Online
Article
Text
id pubmed-5350595
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53505952017-03-21 Statin use and all-cause and cancer mortality: BioBank Japan cohort Yokomichi, Hiroshi Nagai, Akiko Hirata, Makoto Tamakoshi, Akiko Kiyohara, Yutaka Kamatani, Yoichiro Muto, Kaori Ninomiya, Toshiharu Matsuda, Koichi Kubo, Michiaki Nakamura, Yusuke Yamagata, Zentaro J Epidemiol Original Article BACKGROUND: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. METHODS: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. Kaplan–Meier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. RESULTS: Our cohort included 41,930 patients with mean ages of 64–66 years and mean body mass indices of 24–25 kg/m(2). Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. CONCLUSIONS: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statin monotherapy could potentially reduce any-organ- and colorectal cancer-related mortality. Elsevier 2017-02-11 /pmc/articles/PMC5350595/ /pubmed/28196737 http://dx.doi.org/10.1016/j.je.2016.12.011 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Yokomichi, Hiroshi
Nagai, Akiko
Hirata, Makoto
Tamakoshi, Akiko
Kiyohara, Yutaka
Kamatani, Yoichiro
Muto, Kaori
Ninomiya, Toshiharu
Matsuda, Koichi
Kubo, Michiaki
Nakamura, Yusuke
Yamagata, Zentaro
Statin use and all-cause and cancer mortality: BioBank Japan cohort
title Statin use and all-cause and cancer mortality: BioBank Japan cohort
title_full Statin use and all-cause and cancer mortality: BioBank Japan cohort
title_fullStr Statin use and all-cause and cancer mortality: BioBank Japan cohort
title_full_unstemmed Statin use and all-cause and cancer mortality: BioBank Japan cohort
title_short Statin use and all-cause and cancer mortality: BioBank Japan cohort
title_sort statin use and all-cause and cancer mortality: biobank japan cohort
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350595/
https://www.ncbi.nlm.nih.gov/pubmed/28196737
http://dx.doi.org/10.1016/j.je.2016.12.011
work_keys_str_mv AT yokomichihiroshi statinuseandallcauseandcancermortalitybiobankjapancohort
AT nagaiakiko statinuseandallcauseandcancermortalitybiobankjapancohort
AT hiratamakoto statinuseandallcauseandcancermortalitybiobankjapancohort
AT tamakoshiakiko statinuseandallcauseandcancermortalitybiobankjapancohort
AT kiyoharayutaka statinuseandallcauseandcancermortalitybiobankjapancohort
AT kamataniyoichiro statinuseandallcauseandcancermortalitybiobankjapancohort
AT mutokaori statinuseandallcauseandcancermortalitybiobankjapancohort
AT ninomiyatoshiharu statinuseandallcauseandcancermortalitybiobankjapancohort
AT matsudakoichi statinuseandallcauseandcancermortalitybiobankjapancohort
AT kubomichiaki statinuseandallcauseandcancermortalitybiobankjapancohort
AT nakamurayusuke statinuseandallcauseandcancermortalitybiobankjapancohort
AT statinuseandallcauseandcancermortalitybiobankjapancohort
AT yamagatazentaro statinuseandallcauseandcancermortalitybiobankjapancohort